About US
Contact us
-
After Starboard Value gets a seat on the board, another activist investor rallies for change at Kenvue: BloombergJohnson & Johnson’s consumer health spinout Kenvue is quickly amassing a track record of being a target for activist investors. Just after relenting in a brewing fight with Starboard Value, the c2025/3/27
-
FDA rejects Hengrui, Elevar's PD-1 cancer drug combination—againJiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor camrelizumab can enter the U.S. market. The FDA has once again issued a c2025/3/27
-
J&J touts $55B in planned US investments over 4 years, including 3 new manufacturing sitesJohnson & Johnson says it willspend$55 billion in the U.S. over the next four years, including by building three new manufacturing sites and expanding others already in its medicines and medtech2025/3/25
-
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival ApellisNovartis’ kidney disease troika keeps marching forward. With a new FDA approval, the company’s Fabhalta has become the first treatmentendorsedby the agency for the ultrarare kidney disease complement2025/3/25
-
Fierce Pharma Asia—AstraZeneca-Alteogen drug delivery deal; Taiho's ADC buyout; WuXi's rosy 2025 outlookAstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to acquire antibody-drug conjugate expert Araris Biotech. WuXi AppTec expects2025/3/20
-
Biotech designed to commercialize Ascendis' endocrinology drugs in China files $86M IPOEndocrine-disease-focused Visen Pharmaceuticals is making its public market debut in Hong Kong, filing papers for an $86.5 million IPO. The China-based biotech was formed in 2018 by Ascendis Pharma a2025/3/20
-
J&J advances Stelara succession scheme with FDA nod for Tremfya in Crohn's diseaseWith another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on the succession plan for its declining autoimmune blockbuster Stelara. Th2025/3/18
-
Alnylam's Amvuttra wins key approval in ATTR-CM, teeing up showdown with PfizerDespite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA interference approach can set it apart from its peers. And now, the Massachusetts-ba2025/3/18
-
Investor group calls for strategy shift as Amarin shares continue to flounder post-Sarissa Capital takeoverActivist investor Sarissa Capital won control over Amarin’s board two years ago on a fierce campaign of stirring up value for shareholders. But after another year of lacklustersalesand declining shar2025/3/13
-
Calling UK 'uninvestable,' pharma giants demand revamp of drug cost control policyGlobal pharma giants AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Novartis, Pfizer and more are calling for the U.K. government to afford the industry more room for growth by revising a2025/3/13